Vor Biopharma (VOR) Competitors $31.28 +3.35 (+11.99%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock VOR vs. URGN, TSHA, PROK, IOVA, RAPP, PHAT, IMNM, PRAX, AVXL, and SANAShould you be buying Vor Biopharma stock or one of its competitors? The main competitors of Vor Biopharma include Urogen Pharma (URGN), Taysha Gene Therapies (TSHA), ProKidney (PROK), Iovance Biotherapeutics (IOVA), Rapport Therapeutics (RAPP), Phathom Pharmaceuticals (PHAT), Immunome (IMNM), Praxis Precision Medicines (PRAX), Anavex Life Sciences (AVXL), and Sana Biotechnology (SANA). These companies are all part of the "pharmaceutical products" industry. Vor Biopharma vs. Its Competitors Urogen Pharma Taysha Gene Therapies ProKidney Iovance Biotherapeutics Rapport Therapeutics Phathom Pharmaceuticals Immunome Praxis Precision Medicines Anavex Life Sciences Sana Biotechnology Vor Biopharma (NASDAQ:VOR) and Urogen Pharma (NASDAQ:URGN) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership. Which has more volatility and risk, VOR or URGN? Vor Biopharma has a beta of 2.05, meaning that its stock price is 105% more volatile than the S&P 500. Comparatively, Urogen Pharma has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500. Is VOR or URGN more profitable? Vor Biopharma has a net margin of 0.00% compared to Urogen Pharma's net margin of -164.44%. Vor Biopharma's return on equity of 0.00% beat Urogen Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Vor BiopharmaN/A N/A N/A Urogen Pharma -164.44%-97,487.15%-59.38% Which has better earnings & valuation, VOR or URGN? Vor Biopharma has higher earnings, but lower revenue than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVor BiopharmaN/AN/AN/A-$273.20-0.11Urogen Pharma$90.40M9.15-$126.87M-$3.32-5.39 Do analysts recommend VOR or URGN? Urogen Pharma has a consensus price target of $32.00, indicating a potential upside of 78.97%. Given Urogen Pharma's higher possible upside, analysts plainly believe Urogen Pharma is more favorable than Vor Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vor Biopharma 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 3.00Urogen Pharma 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do institutionals and insiders have more ownership in VOR or URGN? 97.3% of Vor Biopharma shares are held by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are held by institutional investors. 0.5% of Vor Biopharma shares are held by company insiders. Comparatively, 4.7% of Urogen Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media refer more to VOR or URGN? In the previous week, Vor Biopharma had 3 more articles in the media than Urogen Pharma. MarketBeat recorded 4 mentions for Vor Biopharma and 1 mentions for Urogen Pharma. Urogen Pharma's average media sentiment score of 1.78 beat Vor Biopharma's score of -0.50 indicating that Urogen Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Urogen Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryVor Biopharma beats Urogen Pharma on 7 of the 13 factors compared between the two stocks. Get Vor Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VOR vs. The Competition Export to ExcelMetricVor BiopharmaBiological Products, Except Diagnostic Substances IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$176.95M$241.80M$2.55B$10.52BDividend YieldN/AN/A2.49%4.57%P/E Ratio-0.11N/A26.4326.62Price / SalesN/A353.86243.90119.62Price / CashN/AN/A51.2461.85Price / BookN/A2.8933.216.45Net IncomeN/A-$111.70M$14.12M$271.57M7 Day Performance-0.38%2.47%0.73%2.83%1 Month Performance-27.93%-35.53%3.71%7.27%1 Year PerformanceN/A88.43%17.51%26.07% Vor Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VORVor Biopharma0.2031 of 5 stars$31.28+12.0%N/AN/A$176.95MN/A-0.11140News CoverageStock SplitGap DownURGNUrogen Pharma4.1363 of 5 stars$18.79-2.4%$32.00+70.3%+32.9%$890.59M$90.40M-5.66200Positive NewsTSHATaysha Gene Therapies2.122 of 5 stars$3.07-5.2%$8.29+169.9%+33.5%$883.86M$8.10M-9.03180PROKProKidney3.4828 of 5 stars$2.48-16.8%$6.25+152.0%+14.2%$876.96M$80K-4.353High Trading VolumeIOVAIovance Biotherapeutics4.3083 of 5 stars$2.27-6.2%$11.90+424.2%-79.1%$875.69M$164.07M-1.85500RAPPRapport Therapeutics3.0498 of 5 stars$23.76+2.4%$31.00+30.5%+23.0%$867.19MN/A-9.50N/APHATPhathom Pharmaceuticals2.4607 of 5 stars$11.84-1.8%$17.50+47.8%-36.3%$855.59M$114.04M-2.50110IMNMImmunome2.1534 of 5 stars$9.21-4.9%$22.89+148.5%-34.8%$842.60M$12.59M-2.9940News CoverageAnalyst ForecastHigh Trading VolumePRAXPraxis Precision Medicines2.2535 of 5 stars$37.71-4.3%$85.88+127.7%-21.4%$829.79M$7.77M-3.07110Positive NewsAVXLAnavex Life Sciences3.8407 of 5 stars$9.37-2.2%$44.00+369.6%+55.0%$822.86MN/A-16.4440SANASana Biotechnology2.9678 of 5 stars$3.22-5.3%$8.00+148.4%-23.5%$808.54MN/A-3.04380 Related Companies and Tools Related Companies URGN Competitors TSHA Competitors PROK Competitors IOVA Competitors RAPP Competitors PHAT Competitors IMNM Competitors PRAX Competitors AVXL Competitors SANA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VOR) was last updated on 9/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vor Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vor Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VOR Stock Alerts